- Home
- Products
- Customized ADCs
- FN1
- Anti-FN1 (Radretumab)-SPDB-DM4 ADC
Anti-FN1 (Radretumab)-SPDB-DM4 ADC (CAT#: ADC-W-1155)
This ADC product is comprised of an anti-FN1 sdAb conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- FN1
- Alternative Names
- FN1; fibronectin 1; fibronectin; CIG; cold insoluble globulin; FINC; GFND2; LETS; migration stimulating factor; MSF; cold-insoluble globulin; migration-stimulating factor; FN; FNZ; ED-B; GFND; DKFZp686H0342; DKFZp686I1370; DKFZp686F10164; DKFZp686O13149;
- Target Entrez Gene ID
- 2335
- Target UniProt ID
- P02751
- Overview
- This gene encodes fibronectin, a glycoprotein present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and in extracellular matrix. The encoded preproprotein is proteolytically processed to generate the mature protein. Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis. The gene has three regions subject to alternative splicing, with the potential to produce 20 different transcript variants, at least one of which encodes an isoform that undergoes proteolytic processing. The full-length nature of some variants has not been determined.
- Overview
- Human Anti-FN1 sdAb, Radretumab
- Generic name
- Radretumab
- Host animal
- Human
- Name
- SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-PCSK9 (Evolocumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2381)
- Anti-CCL2 (Carlumab)-SMCC-DM1 ADC (CAT#: ADC-W-752)
- Anti-MET (Onartuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1542)
- Anti-IL12+IL23 (Ustekinumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1956)
- Anti-MS4A1 (Obinutuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2472)
- Anti-CD37-VC-MMAE ADC (CAT#: ADC-W-486)
- Anti-PCSK9 (Bococizumab)-SPDB-DM4 ADC (CAT#: ADC-W-2229)
- Anti-FOLH1 (MLN591)-thioester-DM1 ADC (CAT#: ADC-W-433)
- Anti-BSG (Ziralimumab)-SMCC-DM1 ADC (CAT#: ADC-W-722)
- Anti-IGF1-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1235)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1155. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1154 | Anti-FN1 (Radretumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-1156 | Anti-FN1 (Radretumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-1157 | Anti-FN1 (Radretumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-508 | Anti-FN1 (clone F8)-SIP-DM1-SH ADC | disulfide linkers | DM1-SH(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine-SH) |
ADC-W-575 | Anti-FN1 (clone F8)-CemCH2-SH ADC | disulfide linker | CemCH2-SH |
CAT# | Product Name | Linker | Payload |
ADC-W-2611 | Anti-MS4A1 (Rituximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2616 | Anti-MS4A1-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-474 | Anti-MSLN-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2595 | Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2590 | Anti-EGFR (Cetuximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-469 | Anti-CA6 (clone huDS6)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2599 | Anti-GPNMB (Glembatumumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2611 | Anti-MS4A1 (Rituximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2621 | Anti-NCAM1 (Lorvotuzumab )-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-474 | Anti-MSLN-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.